Analysts Back Restaurants, Split on Biotech

Darden Restaurants leads the positive analyst action today. The DRI consensus target price rose to $226.23, up from $225.58. The restaurant operator holds a strong buy-leaning consensus with 18 buy ratings. Short interest sits at just 5.1% of free float.

Homebuilder LEN faces pressure. Analysts trimmed the average target to $89.50 from $90.14. The housing sector remains in focus as affordability concerns weigh on sentiment. Short interest at 8.8% of free float reflects ongoing bearish positioning.

GILD scored an upward target price revision today. The average consensus price climbed to $157.57 from $157.04. Gilead carries 23 hold ratings and zero sells — a rare profile for a $156 billion biopharma.

BIIB saw the opposite treatment. The Biogen average target slipped to $220.13. With 21 sell ratings against just one buy, the consensus on the Alzheimer drug maker remains deeply cautious.

GIS also took a target cut. General Mills dropped to $37.00 from $37.56 as the packaged food sector struggles with volume pressure and shifting consumer habits.

SCHW and MTB both received upward target revisions. Both regional financial names benefit from a steeper yield curve and improving net interest margin expectations.